{
  "as_of": "2026-11-02",
  "track": "kras",
  "source_url": "https://drugnews.com.tw/en/asia-kras-leaders.html",
  "headers": [
    "rank",
    "asset",
    "inn",
    "originator",
    "country",
    "target",
    "mechanism",
    "highest_stage",
    "indications",
    "trial_ids",
    "overseas_rights_holder",
    "deal_date",
    "upfront",
    "total_value",
    "latest_event",
    "latest_event_date",
    "source_urls",
    "source_date"
  ],
  "rows": [
    [
      "1",
      "Fulzerasib (GFH925 / IBI351; brand Dupert)",
      "fulzerasib",
      "GenFleet Therapeutics (Shanghai) Inc.",
      "China",
      "KRAS G12C",
      "Oral KRAS G12C inhibitor",
      "Approved — China (2024-08)",
      "KRAS G12C NSCLC after ≥1 systemic therapy (approved Mainland China 2024-08; Macao 2025-06); CRC (CDE BTD); 1L NSCLC + cetuximab (KROCUS Ph1b/2)",
      "NCT05005234 | NCT05756153",
      "Innovent Biologics (Greater China licensee); ex-China rights returned to GenFleet after option termination (Jan 2024)",
      "2021-09-01",
      "USD 22m",
      "USD 262m (USD 22m upfront + up to USD 240m milestones; ex-China option terminated 2024-01)",
      "GenFleet H1-2026 interim results: fulzerasib on China NRDL (Dec 2025), Macao approval (Jun 2025); USD 20m option-termination fee to Innovent being paid in instalments",
      "2026-08-21",
      "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100175.pdf | https://www.stocktitan.net/news/IVBIY/innovent-and-gen-fleet-announce-exclusive-global-license-agreement-d8wq6d1hbh6f.html | https://clinicaltrials.gov/study/NCT05005234 | https://www.pharmafocusasia.com/index.php/news/genfleet-announces-approval-of-kras-g12c-inhibitor-for-advanced-lung-cancer",
      "2026-08-21"
    ],
    [
      "2",
      "Garsorasib (D-1553; brand An Fang Ning)",
      "garsorasib",
      "InventisBio Co., Ltd.",
      "China",
      "KRAS G12C",
      "Oral KRAS G12C inhibitor",
      "Approved — China (2024-11)",
      "KRAS G12C NSCLC after ≥1 systemic therapy (approved); 2L NSCLC vs docetaxel (Ph3); 1L non-squamous NSCLC + IN10018 (Ph3)",
      "NCT05383898 | NCT06300177 | NCT07174908",
      "Chia Tai Tianqing / Sino Biopharm (Mainland China licensee); no ex-China licensee reported",
      "2023-08",
      "Not disclosed",
      "Not disclosed",
      "Phase 3 of IN10018 + garsorasib vs PD-1 + chemo in 1L KRAS G12C non-squamous NSCLC started (sponsor InxMed)",
      "2025-09-10",
      "https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0313/2024031300431.pdf | https://clinicaltrials.gov/study/NCT07174908 | https://clinicaltrials.gov/study/NCT06300177 | https://www.acnnewswire.com/press-release/english/97226/ | https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-november-2024",
      "2026-03-03"
    ],
    [
      "3",
      "Glecirasib (JAB-21822)",
      "glecirasib",
      "Jacobio Pharmaceuticals (Beijing)",
      "China",
      "KRAS G12C",
      "Oral KRAS G12C inhibitor",
      "Approved — China (2025-05)",
      "KRAS G12C NSCLC after ≥1 systemic therapy (approved); 1L NSCLC + sitneprotafib (Ph3, CDE BTD); CRC ≥3L (Ph3 design approved); pancreatic/basket (pivotal Ph2; FDA & EMA orphan)",
      "NCT05009329 | NCT05276726 | NCT06008288",
      "Allist Pharmaceuticals (Greater China licensee); Jacobio retains ex-China rights, no ex-China licensee reported",
      "2024-08-30",
      "RMB 150m (plus RMB 22.79m R&D reimbursement)",
      "Not disclosed (RMB 50m approval milestone paid 2025)",
      "Jacobio H1-2026 interim results: CDE Breakthrough Therapy Designation (May 2026) for glecirasib + sitneprotafib in 1L KRAS G12C NSCLC; on NRDL since Dec 2025",
      "2026-08-24",
      "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401425.pdf | https://jacobiopharma.com/en/node/684 | https://www.jacobiopharma.com/en/node/651 | https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0521/2024052100957.pdf",
      "2026-08-24"
    ],
    [
      "4",
      "HRS-4642",
      "—",
      "Jiangsu Hengrui Pharmaceuticals",
      "China",
      "KRAS G12D",
      "Selective KRAS G12D inhibitor (intravenous injection)",
      "Phase 3 — China (2025-11)",
      "1L metastatic PDAC + nab-paclitaxel/gemcitabine (Ph3); perioperative PDAC (Ph3, not yet recruiting); KRAS G12D solid tumors (Ph1/2)",
      "NCT07232875 | NCT07900789 | NCT05533463",
      "None reported",
      "—",
      "—",
      "—",
      "Second Phase 3 (perioperative pancreatic cancer, HRS-4642 + antitumor agents vs standard therapy) registered on ClinicalTrials.gov",
      "2026-10-28",
      "https://clinicaltrials.gov/study/NCT07232875 | https://clinicaltrials.gov/study/NCT07900789 | https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/a-first-in-human-phase-i-study-of-a-novel-kras-g12d-inhibitor-hrs-4642-in-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation | https://www.pharnexcloud.com/zixun/zcsp_276592",
      "2026-10-28"
    ],
    [
      "5",
      "GFH375 / VS-7375",
      "—",
      "GenFleet Therapeutics (Shanghai) Inc.",
      "China",
      "KRAS G12D",
      "Oral KRAS G12D (ON/OFF) inhibitor",
      "Phase 3 — China (2025-12)",
      "Previously treated KRAS G12D metastatic PDAC (Ph3); pretreated KRAS G12D NSCLC vs docetaxel (Ph3); both CDE BTD (H1 2026); US Ph1/2 by Verastem (FDA Fast Track)",
      "NCT07262567 | NCT07668752 | NCT06500676",
      "Verastem Oncology (ex-Greater China; option exercised Jan 2025)",
      "2023-08-24",
      "USD 2m upfront (2023 option deal) + USD 6m option-exercise payment (2025-01)",
      "Up to USD 622m (option-deal total covering up to three GenFleet programs)",
      "Phase 3 of GFH375 vs docetaxel in pretreated KRAS G12D NSCLC started in China",
      "2026-07-27",
      "https://clinicaltrials.gov/study/NCT07262567 | https://clinicaltrials.gov/study/NCT07668752 | https://www.sec.gov/Archives/edgar/data/1526119/000155837025010757/vstm-20250630x10q.htm | https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-exercises-option-early-license-vs-7375-oral | https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100175.pdf",
      "2026-08-21"
    ],
    [
      "6",
      "Setidegrasib (ASP3082)",
      "setidegrasib",
      "Astellas Pharma Inc.",
      "Japan",
      "KRAS G12D",
      "KRAS G12D-selective protein degrader (binds KRAS G12D and an E3 ligase)",
      "Phase 3 — Global (2026-02)",
      "1L KRAS G12D metastatic PDAC + mFOLFIRINOX/NALIRIFOX (Ph3); KRAS G12D NSCLC after platinum + CPI vs docetaxel (Ph3)",
      "NCT07409272 | NCT07566052 | NCT05382559",
      "None reported (in-house Astellas discovery)",
      "—",
      "—",
      "—",
      "Second Phase 3 (setidegrasib vs docetaxel in KRAS G12D NSCLC) started enrolling",
      "2026-04-28",
      "https://filecache.mediaroom.com/mr5mr_globalastellas/180497/20260415_en_1.pdf | https://clinicaltrials.gov/study/NCT07409272 | https://clinicaltrials.gov/study/NCT07566052",
      "2026-10-20"
    ],
    [
      "7",
      "HRS-7058",
      "—",
      "Jiangsu Hengrui Pharmaceuticals (via subsidiary Shandong Suncadia Medicine)",
      "China",
      "KRAS G12C",
      "Oral irreversible KRAS G12C (OFF-state) inhibitor",
      "Phase 3 — China (registered 2026-05; not yet recruiting)",
      "KRAS G12C NSCLC after standard therapy vs investigator-chosen KRAS G12C inhibitor (Ph3); pancreatic cancer (Ph2); KRAS G12C solid tumors (Ph1)",
      "NCT07601048 | NCT07589569 | NCT06383871",
      "None reported",
      "—",
      "—",
      "—",
      "Phase 2 in pancreatic cancer started (after Ph3 head-to-head vs fulzerasib/garsorasib/glecirasib was registered 2026-05-22)",
      "2026-06-04",
      "https://clinicaltrials.gov/study/NCT07601048 | https://clinicaltrials.gov/study/NCT07589569 | https://clinicaltrials.gov/study/NCT06383871 | https://static.weeklyonstock.com/25/1101/wbf163129.html",
      "2026-06-11"
    ],
    [
      "8",
      "HS-10370",
      "—",
      "Jiangsu Hansoh Pharmaceutical",
      "China",
      "KRAS G12C",
      "Oral, highly selective small-molecule KRAS G12C inhibitor",
      "Phase 3 — China (registered 2026-09; not yet recruiting)",
      "1L KRAS G12C non-squamous NSCLC + platinum doublet ± adebrelimab vs tislelizumab + chemo (Ph3); advanced solid tumors (Ph1/2, Ph1b combos)",
      "NCT07822542 | NCT05367778 | NCT06594874",
      "None reported",
      "—",
      "—",
      "—",
      "Phase 3 1L NSCLC trial registered on ClinicalTrials.gov (planned start 2026-10-31)",
      "2026-09-16",
      "https://clinicaltrials.gov/study/NCT07822542 | https://clinicaltrials.gov/study/NCT05367778",
      "2026-09-16"
    ]
  ],
  "row_sources": [
    [
      {
        "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100175.pdf",
        "source_date": "2026-08-21"
      },
      {
        "url": "https://www.stocktitan.net/news/IVBIY/innovent-and-gen-fleet-announce-exclusive-global-license-agreement-d8wq6d1hbh6f.html",
        "source_date": "2026-08-21"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05005234",
        "source_date": "2026-08-21"
      },
      {
        "url": "https://www.pharmafocusasia.com/index.php/news/genfleet-announces-approval-of-kras-g12c-inhibitor-for-advanced-lung-cancer",
        "source_date": "2026-08-21"
      }
    ],
    [
      {
        "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0313/2024031300431.pdf",
        "source_date": "2026-03-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07174908",
        "source_date": "2026-03-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06300177",
        "source_date": "2026-03-03"
      },
      {
        "url": "https://www.acnnewswire.com/press-release/english/97226/",
        "source_date": "2026-03-03"
      },
      {
        "url": "https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-november-2024",
        "source_date": "2026-03-03"
      }
    ],
    [
      {
        "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401425.pdf",
        "source_date": "2026-08-24"
      },
      {
        "url": "https://jacobiopharma.com/en/node/684",
        "source_date": "2026-08-24"
      },
      {
        "url": "https://www.jacobiopharma.com/en/node/651",
        "source_date": "2026-08-24"
      },
      {
        "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0521/2024052100957.pdf",
        "source_date": "2026-08-24"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07232875",
        "source_date": "2026-10-28"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07900789",
        "source_date": "2026-10-28"
      },
      {
        "url": "https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/a-first-in-human-phase-i-study-of-a-novel-kras-g12d-inhibitor-hrs-4642-in-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation",
        "source_date": "2026-10-28"
      },
      {
        "url": "https://www.pharnexcloud.com/zixun/zcsp_276592",
        "source_date": "2026-10-28"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07262567",
        "source_date": "2026-08-21"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07668752",
        "source_date": "2026-08-21"
      },
      {
        "url": "https://www.sec.gov/Archives/edgar/data/1526119/000155837025010757/vstm-20250630x10q.htm",
        "source_date": "2026-08-21"
      },
      {
        "url": "https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-exercises-option-early-license-vs-7375-oral",
        "source_date": "2026-08-21"
      },
      {
        "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100175.pdf",
        "source_date": "2026-08-21"
      }
    ],
    [
      {
        "url": "https://filecache.mediaroom.com/mr5mr_globalastellas/180497/20260415_en_1.pdf",
        "source_date": "2026-10-20"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07409272",
        "source_date": "2026-10-20"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07566052",
        "source_date": "2026-10-20"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07601048",
        "source_date": "2026-06-11"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07589569",
        "source_date": "2026-06-11"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06383871",
        "source_date": "2026-06-11"
      },
      {
        "url": "https://static.weeklyonstock.com/25/1101/wbf163129.html",
        "source_date": "2026-06-11"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07822542",
        "source_date": "2026-09-16"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05367778",
        "source_date": "2026-09-16"
      }
    ]
  ],
  "records": [
    {
      "rank": "1",
      "asset": "Fulzerasib (GFH925 / IBI351; brand Dupert)",
      "inn": "fulzerasib",
      "originator": "GenFleet Therapeutics (Shanghai) Inc.",
      "country": "China",
      "target": "KRAS G12C",
      "mechanism": "Oral KRAS G12C inhibitor",
      "highest_stage": "Approved — China (2024-08)",
      "indications": "KRAS G12C NSCLC after ≥1 systemic therapy (approved Mainland China 2024-08; Macao 2025-06); CRC (CDE BTD); 1L NSCLC + cetuximab (KROCUS Ph1b/2)",
      "trial_ids": "NCT05005234 | NCT05756153",
      "overseas_rights_holder": "Innovent Biologics (Greater China licensee); ex-China rights returned to GenFleet after option termination (Jan 2024)",
      "deal_date": "2021-09-01",
      "upfront": "USD 22m",
      "total_value": "USD 262m (USD 22m upfront + up to USD 240m milestones; ex-China option terminated 2024-01)",
      "latest_event": "GenFleet H1-2026 interim results: fulzerasib on China NRDL (Dec 2025), Macao approval (Jun 2025); USD 20m option-termination fee to Innovent being paid in instalments",
      "latest_event_date": "2026-08-21",
      "source_urls": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100175.pdf | https://www.stocktitan.net/news/IVBIY/innovent-and-gen-fleet-announce-exclusive-global-license-agreement-d8wq6d1hbh6f.html | https://clinicaltrials.gov/study/NCT05005234 | https://www.pharmafocusasia.com/index.php/news/genfleet-announces-approval-of-kras-g12c-inhibitor-for-advanced-lung-cancer",
      "source_date": "2026-08-21"
    },
    {
      "rank": "2",
      "asset": "Garsorasib (D-1553; brand An Fang Ning)",
      "inn": "garsorasib",
      "originator": "InventisBio Co., Ltd.",
      "country": "China",
      "target": "KRAS G12C",
      "mechanism": "Oral KRAS G12C inhibitor",
      "highest_stage": "Approved — China (2024-11)",
      "indications": "KRAS G12C NSCLC after ≥1 systemic therapy (approved); 2L NSCLC vs docetaxel (Ph3); 1L non-squamous NSCLC + IN10018 (Ph3)",
      "trial_ids": "NCT05383898 | NCT06300177 | NCT07174908",
      "overseas_rights_holder": "Chia Tai Tianqing / Sino Biopharm (Mainland China licensee); no ex-China licensee reported",
      "deal_date": "2023-08",
      "upfront": "Not disclosed",
      "total_value": "Not disclosed",
      "latest_event": "Phase 3 of IN10018 + garsorasib vs PD-1 + chemo in 1L KRAS G12C non-squamous NSCLC started (sponsor InxMed)",
      "latest_event_date": "2025-09-10",
      "source_urls": "https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0313/2024031300431.pdf | https://clinicaltrials.gov/study/NCT07174908 | https://clinicaltrials.gov/study/NCT06300177 | https://www.acnnewswire.com/press-release/english/97226/ | https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-november-2024",
      "source_date": "2026-03-03"
    },
    {
      "rank": "3",
      "asset": "Glecirasib (JAB-21822)",
      "inn": "glecirasib",
      "originator": "Jacobio Pharmaceuticals (Beijing)",
      "country": "China",
      "target": "KRAS G12C",
      "mechanism": "Oral KRAS G12C inhibitor",
      "highest_stage": "Approved — China (2025-05)",
      "indications": "KRAS G12C NSCLC after ≥1 systemic therapy (approved); 1L NSCLC + sitneprotafib (Ph3, CDE BTD); CRC ≥3L (Ph3 design approved); pancreatic/basket (pivotal Ph2; FDA & EMA orphan)",
      "trial_ids": "NCT05009329 | NCT05276726 | NCT06008288",
      "overseas_rights_holder": "Allist Pharmaceuticals (Greater China licensee); Jacobio retains ex-China rights, no ex-China licensee reported",
      "deal_date": "2024-08-30",
      "upfront": "RMB 150m (plus RMB 22.79m R&D reimbursement)",
      "total_value": "Not disclosed (RMB 50m approval milestone paid 2025)",
      "latest_event": "Jacobio H1-2026 interim results: CDE Breakthrough Therapy Designation (May 2026) for glecirasib + sitneprotafib in 1L KRAS G12C NSCLC; on NRDL since Dec 2025",
      "latest_event_date": "2026-08-24",
      "source_urls": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401425.pdf | https://jacobiopharma.com/en/node/684 | https://www.jacobiopharma.com/en/node/651 | https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0521/2024052100957.pdf",
      "source_date": "2026-08-24"
    },
    {
      "rank": "4",
      "asset": "HRS-4642",
      "inn": "—",
      "originator": "Jiangsu Hengrui Pharmaceuticals",
      "country": "China",
      "target": "KRAS G12D",
      "mechanism": "Selective KRAS G12D inhibitor (intravenous injection)",
      "highest_stage": "Phase 3 — China (2025-11)",
      "indications": "1L metastatic PDAC + nab-paclitaxel/gemcitabine (Ph3); perioperative PDAC (Ph3, not yet recruiting); KRAS G12D solid tumors (Ph1/2)",
      "trial_ids": "NCT07232875 | NCT07900789 | NCT05533463",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Second Phase 3 (perioperative pancreatic cancer, HRS-4642 + antitumor agents vs standard therapy) registered on ClinicalTrials.gov",
      "latest_event_date": "2026-10-28",
      "source_urls": "https://clinicaltrials.gov/study/NCT07232875 | https://clinicaltrials.gov/study/NCT07900789 | https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/a-first-in-human-phase-i-study-of-a-novel-kras-g12d-inhibitor-hrs-4642-in-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation | https://www.pharnexcloud.com/zixun/zcsp_276592",
      "source_date": "2026-10-28"
    },
    {
      "rank": "5",
      "asset": "GFH375 / VS-7375",
      "inn": "—",
      "originator": "GenFleet Therapeutics (Shanghai) Inc.",
      "country": "China",
      "target": "KRAS G12D",
      "mechanism": "Oral KRAS G12D (ON/OFF) inhibitor",
      "highest_stage": "Phase 3 — China (2025-12)",
      "indications": "Previously treated KRAS G12D metastatic PDAC (Ph3); pretreated KRAS G12D NSCLC vs docetaxel (Ph3); both CDE BTD (H1 2026); US Ph1/2 by Verastem (FDA Fast Track)",
      "trial_ids": "NCT07262567 | NCT07668752 | NCT06500676",
      "overseas_rights_holder": "Verastem Oncology (ex-Greater China; option exercised Jan 2025)",
      "deal_date": "2023-08-24",
      "upfront": "USD 2m upfront (2023 option deal) + USD 6m option-exercise payment (2025-01)",
      "total_value": "Up to USD 622m (option-deal total covering up to three GenFleet programs)",
      "latest_event": "Phase 3 of GFH375 vs docetaxel in pretreated KRAS G12D NSCLC started in China",
      "latest_event_date": "2026-07-27",
      "source_urls": "https://clinicaltrials.gov/study/NCT07262567 | https://clinicaltrials.gov/study/NCT07668752 | https://www.sec.gov/Archives/edgar/data/1526119/000155837025010757/vstm-20250630x10q.htm | https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-exercises-option-early-license-vs-7375-oral | https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100175.pdf",
      "source_date": "2026-08-21"
    },
    {
      "rank": "6",
      "asset": "Setidegrasib (ASP3082)",
      "inn": "setidegrasib",
      "originator": "Astellas Pharma Inc.",
      "country": "Japan",
      "target": "KRAS G12D",
      "mechanism": "KRAS G12D-selective protein degrader (binds KRAS G12D and an E3 ligase)",
      "highest_stage": "Phase 3 — Global (2026-02)",
      "indications": "1L KRAS G12D metastatic PDAC + mFOLFIRINOX/NALIRIFOX (Ph3); KRAS G12D NSCLC after platinum + CPI vs docetaxel (Ph3)",
      "trial_ids": "NCT07409272 | NCT07566052 | NCT05382559",
      "overseas_rights_holder": "None reported (in-house Astellas discovery)",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Second Phase 3 (setidegrasib vs docetaxel in KRAS G12D NSCLC) started enrolling",
      "latest_event_date": "2026-04-28",
      "source_urls": "https://filecache.mediaroom.com/mr5mr_globalastellas/180497/20260415_en_1.pdf | https://clinicaltrials.gov/study/NCT07409272 | https://clinicaltrials.gov/study/NCT07566052",
      "source_date": "2026-10-20"
    },
    {
      "rank": "7",
      "asset": "HRS-7058",
      "inn": "—",
      "originator": "Jiangsu Hengrui Pharmaceuticals (via subsidiary Shandong Suncadia Medicine)",
      "country": "China",
      "target": "KRAS G12C",
      "mechanism": "Oral irreversible KRAS G12C (OFF-state) inhibitor",
      "highest_stage": "Phase 3 — China (registered 2026-05; not yet recruiting)",
      "indications": "KRAS G12C NSCLC after standard therapy vs investigator-chosen KRAS G12C inhibitor (Ph3); pancreatic cancer (Ph2); KRAS G12C solid tumors (Ph1)",
      "trial_ids": "NCT07601048 | NCT07589569 | NCT06383871",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Phase 2 in pancreatic cancer started (after Ph3 head-to-head vs fulzerasib/garsorasib/glecirasib was registered 2026-05-22)",
      "latest_event_date": "2026-06-04",
      "source_urls": "https://clinicaltrials.gov/study/NCT07601048 | https://clinicaltrials.gov/study/NCT07589569 | https://clinicaltrials.gov/study/NCT06383871 | https://static.weeklyonstock.com/25/1101/wbf163129.html",
      "source_date": "2026-06-11"
    },
    {
      "rank": "8",
      "asset": "HS-10370",
      "inn": "—",
      "originator": "Jiangsu Hansoh Pharmaceutical",
      "country": "China",
      "target": "KRAS G12C",
      "mechanism": "Oral, highly selective small-molecule KRAS G12C inhibitor",
      "highest_stage": "Phase 3 — China (registered 2026-09; not yet recruiting)",
      "indications": "1L KRAS G12C non-squamous NSCLC + platinum doublet ± adebrelimab vs tislelizumab + chemo (Ph3); advanced solid tumors (Ph1/2, Ph1b combos)",
      "trial_ids": "NCT07822542 | NCT05367778 | NCT06594874",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Phase 3 1L NSCLC trial registered on ClinicalTrials.gov (planned start 2026-10-31)",
      "latest_event_date": "2026-09-16",
      "source_urls": "https://clinicaltrials.gov/study/NCT07822542 | https://clinicaltrials.gov/study/NCT05367778",
      "source_date": "2026-09-16"
    }
  ]
}